PMID- 35335097
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231105
IS  - 2076-393X (Print)
IS  - 2076-393X (Linking)
VI  - 10
IP  - 3
DP  - 2022 Mar 18
TI  - Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan 
      Healthcare Workers.
LID - 465 [pii]
LID - 10.3390/vaccines10030465 [doi]
AB  - Data about the duration of antibodies after vaccination show that the protection 
      against SARS-CoV-2 infection begins to decline over time. This study aims to 
      determine anti-SARS-CoV-2 anti-S IgG levels in healthcare workers five months 
      after the second vaccination dose. We collected samples from 82 participants who 
      were fully vaccinated with ChAdOx1 nCoV-19 or BBIBP-CorV. We assessed 
      anti-SARS-CoV-2 IgG antibodies using a Euroimmun ELISA and an Abbott Architect  
      SARS-CoV-2 IgG test. Of the 82 participants, 65.85% were seropositive for IgG 
      using ELISA, and 86.59% were positive for IgG according to the Abbott Architect  
      test. Individuals vaccinated with the ChAdOx1 nCoV-19 vaccine had a median 
      anti-S1 antibody level of 1.810 AU/mL [interquartile range (IQR), 1.080-3.7340] 
      and 171.7 AU/mL [79.9-684.6] according to the Euroimmun ELISA and Abbott 
      Architect test, respectively. These tests indicated that people vaccinated with 
      BBIBP-CorV had a median anti-S1 antibody level of 1.840 AU/mL [0.810-2.960] and 
      126.7 AU/mL [54.9-474.3], respectively. Statistical analysis showed no 
      significant difference between the positivity rates of the vaccinated 
      individuals, either for gender or for age. In addition, we found no significant 
      difference between the two vaccines. Our study provides information on the 
      longevity of the anti-SARS-CoV-2 IgG antibodies in people at least five months 
      after vaccination.
FAU - Assaid, Najlaa
AU  - Assaid N
AUID- ORCID: 0000-0003-2658-1619
AD  - Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, 
      Place Louis Pasteur, Casablanca 20360, Morocco.
AD  - Health and Environment Laboratory, Molecular Genetics and Immunophysiopathology 
      Research Team, Ain Chock Faculty of Sciences, University of Hassan II Casablanca 
      (UH2C), Casablanca 20100, Morocco.
FAU - Arich, Soukaina
AU  - Arich S
AUID- ORCID: 0000-0002-3838-333X
AD  - Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, 
      Place Louis Pasteur, Casablanca 20360, Morocco.
FAU - Charoute, Hicham
AU  - Charoute H
AUID- ORCID: 0000-0002-9338-6744
AD  - Research Unit of Epidemiology, Biostatistics and Bioinformatics, Institut Pasteur 
      du Maroc, Casablanca 20360, Morocco.
FAU - Akarid, Khadija
AU  - Akarid K
AD  - Health and Environment Laboratory, Molecular Genetics and Immunophysiopathology 
      Research Team, Ain Chock Faculty of Sciences, University of Hassan II Casablanca 
      (UH2C), Casablanca 20100, Morocco.
FAU - Ezzikouri, Sayeh
AU  - Ezzikouri S
AUID- ORCID: 0000-0002-3982-6163
AD  - Viral Hepatitis Laboratory, Virology Unit, Institut Pasteur du Maroc, Casablanca 
      20360, Morocco.
FAU - Maaroufi, Abderrahmane
AU  - Maaroufi A
AD  - Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, 
      Place Louis Pasteur, Casablanca 20360, Morocco.
FAU - Sarih, M'hammed
AU  - Sarih M
AD  - Service de Parasitologie et des Maladies Vectorielles, Institut Pasteur du Maroc, 
      Place Louis Pasteur, Casablanca 20360, Morocco.
LA  - eng
GR  - No Grant Number/International Network of Pasteur Institutes/
PT  - Journal Article
DEP - 20220318
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8952418
OTO - NOTNLM
OT  - BBIBP-CorV
OT  - COVID vaccine
OT  - ChAdOx1 nCoV-19
OT  - antibody response
EDAT- 2022/03/27 06:00
MHDA- 2022/03/27 06:01
CRDT- 2022/03/26 01:02
PHST- 2022/02/08 00:00 [received]
PHST- 2022/03/12 00:00 [revised]
PHST- 2022/03/14 00:00 [accepted]
PHST- 2022/03/26 01:02 [entrez]
PHST- 2022/03/27 06:00 [pubmed]
PHST- 2022/03/27 06:01 [medline]
AID - vaccines10030465 [pii]
AID - 10.3390/vaccines10030465 [doi]
PST - epublish
SO  - Vaccines (Basel). 2022 Mar 18;10(3):465. doi: 10.3390/vaccines10030465.